Inhibitors of RAF kinases

1. A compound, or pharmaceutically acceptable salt or solvate thereof, having the structure of Formula (II):

wherein,

W is NH, NR 7 ;

X is C—H;

Y is C—H;

R is H, C1-C8 optionally substituted alkyl, C3-C6 optionally substituted cycloalkyl, C4-C8 optionally substituted cycloalkylalkyl, C3-C6 optionally substituted heterocyclyl, C3-C6 optionally substituted heterocyclylalkyl, or C1-C8 optionally substituted alkyl-CO—;

R 1 is C1-C3 optionally substituted alkyl, and q is 0, 1, or 2;

R 2 is H, D or F;

R 4 is halogen, optionally substituted C1-C3 alkyl, —CD 3 , or optionally substituted C1-C3 alkoxy;

R 6 is H, D, Cl or F;

R 7 is C1-C8 optionally substituted alkyl; or R is not H, and R and R 7 optionally join to form an optionally substituted heterocyclyl ring;

R c is H or D;

Z is (a)

wherein m is 0, 1, 2, or 3; p is 0, 1, 2, 3, or 4; and

each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —S-alkyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl; or two R 11 groups together form an oxo; or

(b)

wherein n is 1, 2, or 3; m is 1, 2, or 3; p is 0, 1, 2, 3, or 4; and

each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —S-alkyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl; or two R 11 groups together form an oxo.

2. The compound of claim 1 , or pharmaceutically acceptable salt or solvate thereof, wherein W is NH.

3. The compound of claim 1 , or pharmaceutically acceptable salt or solvate thereof, wherein W is NR 7 .

4. The compound of claim 1 , or pharmaceutically acceptable salt or solvate thereof, wherein W is NR 7 , R is not H, and R and R 7 join to form an optionally substituted heterocyclyl ring.

5. The compound of claim 4 , or pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted heterocyclyl ring is a 1-aztidinyl, 1-pyrrolidinyl, or 1-piperidinyl ring.

6. The compound of claim 5 , or pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted heterocyclyl ring is substituted with at least one substituent selected from —OH, halogen, optionally substituted C1-C6 alkyl, or optionally substituted C1-C6 alkoxy.

7. The compound of claim 2 , or pharmaceutically acceptable salt or solvate thereof, wherein R is C1-C8 optionally substituted alkyl, C3-C6 optionally substituted cycloalkyl, C4-C6 optionally substituted cycloalkylalkyl, C3-C6 optionally substituted heterocyclyl, or C3-C6 optionally substituted heterocyclylalkyl.

8. The compound of claim 7 , or pharmaceutically acceptable salt or solvate thereof, wherein R is C1-C6 optionally substituted alkyl.

9. The compound of claim 7 , or pharmaceutically acceptable salt or solvate thereof, wherein R is C1-C3 optionally substituted alkyl.

10. The compound of claim 7 , or pharmaceutically acceptable salt or solvate thereof, wherein R is C1-C2 optionally substituted alkyl.

11. The compound of claim 7 , or pharmaceutically acceptable salt or solvate thereof, wherein R is C1-C6 optionally substituted alkyl and the alkyl is substituted with at least one hydroxyl.

12. The compound of claim 7 , or pharmaceutically acceptable salt or solvate thereof, wherein R is C3-C6 optionally substituted cycloalkyl.

13. The compound of claim 7 , or pharmaceutically acceptable salt or solvate thereof, wherein R is C4-C6 optionally substituted cycloalkylalkyl.

14. The compound of claim 7 , or pharmaceutically acceptable salt or solvate thereof, wherein R is C3-C6 optionally substituted heterocyclyl.

15. The compound of claim 7 , or pharmaceutically acceptable salt or solvate thereof, wherein R is C3-C6 optionally substituted heterocyclylalkyl.

16. The compound of claim 1 , or pharmaceutically acceptable salt or solvate thereof, wherein R 1 is C1 optionally substituted alkyl.

17. The compound of claim 1 , or pharmaceutically acceptable salt or solvate thereof, wherein q is 0.

18. The compound of claim 1 , or pharmaceutically acceptable salt or solvate thereof, wherein q is 1.

19. The compound of claim 1 , or pharmaceutically acceptable salt or solvate thereof, wherein Z is

20. The compound of claim 1 , or pharmaceutically acceptable salt or solvate thereof, wherein Z is

21. The compound of claim 1 , or pharmaceutically acceptable salt or solvate thereof, wherein m is 1.

22. The compound of claim 1 , or pharmaceutically acceptable salt or solvate thereof, wherein p is 1.

23. The compound of claim 20 , or pharmaceutically acceptable salt or solvate thereof, wherein n is 1.

24. The compound of claim 1 , or pharmaceutically acceptable salt or solvate thereof, wherein R 11 is optionally substituted C1-C2 alkyl.

25. The compound of claim 1 , or pharmaceutically acceptable salt or solvate thereof, wherein R 11 is —CF 3 .

26. The compound of claim 1 , or pharmaceutically acceptable salt or solvate thereof, wherein R 11 is —CH 2 CF 3 .

27. The compound of claim 1 , or pharmaceutically acceptable salt or solvate thereof, wherein R 11 is —OCF 3 .

28. The compound of claim 1 , or pharmaceutically acceptable salt or solvate thereof, wherein R 4 is CH 3 .

29. The compound of claim 1 , or pharmaceutically acceptable salt or solvate thereof, wherein R 2 is H, and R 6 is H.

30. A pharmaceutical composition comprising a compound of Formula (II), or pharmaceutically acceptable salt or solvate thereof, as described in claim 1 , and a pharmaceutically acceptable excipient.